Cytokine-induced killer cell therapy - Shanghai Pharmaceuticals Holding
Alternative Names: CIK - Shanghai Pharmaceuticals HoldingLatest Information Update: 01 Sep 2023
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Cytokine induced killer cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Lung cancer
Most Recent Events
- 24 Aug 2023 Phase-I clinical trials in Lung cancer in China (Parenteral), prior to August 2023 (Shanghai Pharmaceuticals Holding pipeline, August 2023)